Syncope secondary to second-degree atrioventricular block with donepezil use
Aneley Hundae1, Aasim Afzal1, Manish D Assar1
1Department of Internal Medicine (Hundae), Division of Cardiology (Afzal, Schussler), Baylor University Medical Center at Dallas; and the Department of Internal Medicine, Texas A&M College of Medicine (Schussler).
Abstract:
Donepezil, an acetylcholinesterase inhibitor, is approved for the treatment of mild to moderate dementia secondary to Alzheimer's disease. Although most prescribers are aware of the common gastrointestinal side effects of donepezil, cardiovascular side effects are rarely observed. Cardiovascular side effects of donepezil have almost always been observed in patients with a history of conduction defects or sick sinus syndrome. We report a case of a woman with early onset Alzheimer's disease and no history of cardiac disease who developed second-degree heart block after a few weeks of therapy with donepezil. Withdrawal of donepezil led to resolution of the atrioventricular block.
Related Concept Videos
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Alzheimer's Disease: Treatment
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...


